Calpain inhibition stabilizes the platelet proteome and reactivity in diabetes

Blood

Volumn 120, Issue 2, 2012, Pages 415-423

  Randriamboavonjy, Voahanginirina ^a   Isaak, Johann ^a   Elgheznawy, Amro ^a   Pistrosch, Frank ^b   Frömel, Timo ^a   Yin, Xiaoke ^c   Badenhoop, Klaus ^a   Heide, Heinrich ^a   Mayr, Manuel ^c   Fleming, Ingrid ^a  

^a GOETHE UNIVERSITY   (Germany)

^b UNIVERSITY HOSPITAL CARL GUSTAV CARUS   (Germany)

^c KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CALCIUM ION; CALPAIN 1; CALPAIN 2; INTEGRIN LINKED KINASE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA 2; PIOGLITAZONE; PLACEBO; RANTES; SARCOPLASMIC RETICULUM CALCIUM TRANSPORTING ADENOSINE TRIPHOSPHATASE; SARCOPLASMIC RETICULUM CALCIUM TRANSPORTING ADENOSINE TRIPHOSPHATASE 2; SEPTIN; SEPTIN 5; SYNTAXIN 4; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG;

ADULT; AGED; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; ENZYME ACTIVATION; ENZYME INHIBITION; FEMALE; HUMAN; LEUKOCYTE AGGREGATION; MALE; MOUSE; NEUTROPHIL CHEMOTAXIS; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PRIORITY JOURNAL; PROTEIN CLEAVAGE; PROTEIN EXPRESSION; PROTEOMICS; THROMBOCYTE; THROMBOCYTE ADHESION; THROMBOCYTE AGGREGATION; THROMBOCYTE FUNCTION;

EID: 84864066901     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2011-12-399980     Document Type: Article

References (47)

1. Sorimachi H, Hata S, Ono Y. Impact of genetic insights into calpain biology. J Biochem. 2011; 150(1):23-37.
2. Croall D, Ersfeld K. The calpains: modular designs and functional diversity. Genome Biol. 2007;8(6):218.
3. Suzuki K, Hata S, Kawabata Y, Sorimachi H. Structure, activation, and biology of calpain. Diabetes. 2004;53(90001):S12-S18. (Pubitemid 38168687)
4. Hood JL, Brooks WH, Roszman TL. Subcellular mobility of the calpain/calpastatin network: an organelle transient. BioEssays. 2006;28(8):850-859. (Pubitemid 44433747)
5. Liu T, Schneider RA, Hoyt DG. Calpastatin is regulated by protein never in mitosis gene A interacting-1 (PIN1) in endothelial cells. Biochem Biophys Res Commun. 2011;414(3):581-586.
6. Shao H, Chou J, Baty CJ, et al. Spatial localization of m-calpain to the plasma Membrane by phosphoinositide biphosphate binding during epidermal growth factor receptor-mediated activation. Mol Cell Biol. 2006;26(14):5481-5496. (Pubitemid 44036214)
7. Beltran L, Chaussade C, Vanhaesebroeck B, Cutillas PR. Calpain interacts with class IA phosphoinositide 3-kinases regulating their stability and signaling activity. Proc Natl Acad Sci U S A. 2011;108(39):16217-16222.
8. Dutt P, Croall D, Arthur JS, et al. m-Calpain is required for preimplantation embryonic development in mice. BMC Dev Biol. 2006;6(1):3.
9. Takano J, Mihira N, Fujioka R, et al. Vital role of the calpain-calpastatin system for placental-integrity-dependent embryonic survival. Mol Cell Biol. 2011;31(19):4097-4106.
10. Azam M, Andrabi SS, Sahr KE, et al. Disruption of the mouse mu-calpain gene reveals an essential role in platelet function. Mol Cell Biol. 2001; 21(6):2213-2220. (Pubitemid 32479641)
11. Kuchay SM, Kim N, Grunz EA, Fay WP, Chishti AH. Double knockouts reveal that protein tyrosine phosphatase 1B is a physiological target of calpain-1 in platelets. Mol Cell Biol. 2007; 27(17):6038-6052. (Pubitemid 47326693)
12. Randriamboavonjy V, Pistrosch F, Bolck B, et al. Platelet sarcoplasmic endoplasmic reticulum Ca2+-ATPase and mu-calpain activity are altered in type 2 diabetes mellitus and restored by rosiglitazone. Circulation. 2008;117(1):52-60. (Pubitemid 350291181)
13. Kuchay SM, Chishti AH. Calpain-mediated regulation of platelet signaling pathways. Curr Opin Hematol. 2007;14(3):249-254. (Pubitemid 46597611)
14. Bogacka I, Xie H, Bray GA, Smith SR. The effect of pioglitazone on peroxisome proliferator-activated receptor-gamma target genes related to lipid storage in vivo. Diabetes Care. 2004;27(7): 1660-1667. (Pubitemid 38857441)
15. Dent J, Kato K, Peng XR, et al. A prototypic platelet septin and its participation in secretion. Proc Natl Acad Sci U S A. 2002;99(5):3064-3069. (Pubitemid 34240586)
16. Schober A, Zernecke A. Chemokines in vascular remodeling. Thromb Haemost. 2007;97(5):730-737. (Pubitemid 46779958)
17. Fong KP, Barry C, Tran AN, et al. Deciphering the human platelet sheddome. Blood. 2011;117(1): e15-e26.
18. Legate KR, Montanez E, Kudlacek O, Fassler R. ILK, PINCH and Parvin: the tIPP of integrin signalling. Nat Rev Mol Cell Biol. 2006;7(1):20-31. (Pubitemid 43361569)
19. Persad S, Attwell S, Gray V, et al. Inhibition of integrin-linked kinase (ILK) suppresses activation of protein kinase B/Akt and induces cell cycle arrest and apoptosis of PTEN-mutant prostate cancer cells. Proc Natl Acad Sci U S A. 2000;97(7): 3207-3212. (Pubitemid 30183280)
20. Persad S, Attwell S, Gray V, et al. Regulation of protein kinase B/Akt-serine 473 phosphorylation by integrin-linked kinase: critical roles for kinase activity and amino acids arginine 211 and serine 343. J Biol Chem. 2001;276(29):27462-27469.
21. Zhang Y, Chen K, Tu Y, et al. Assembly of the PINCH-ILK-CH-ILKBP complex precedes and is essential for localization of each component to cell-matrix adhesion sites. J Cell Sci. 2002; 115(Pt 24):4777-4786. (Pubitemid 36054631)
22. Franco SJ, Rodgers MA, Perrin BJ, et al. Calpain-mediated proteolysis of talin regulates adhesion dynamics. Nat Cell Biol. 2004;6(10):977-983. (Pubitemid 39359850)
23. Chan KT, Bennin DA, Huttenlocher A. Regulation of adhesion dynamics by calpain-mediated proteolysis of focal adhesion kinase (FAK). J Biol Chem. 2010;285(15):11418-11426.
24. Lubisch W, Beckenbach E, Bopp S, et al. Benzoylalanine-derived ketoamides carrying vinylbenzyl amino residues: discovery of potent water-soluble calpain inhibitors with oral bioavailability. J Med Chem. 2003;46(12):2404-2412. (Pubitemid 36637924)
25. Massberg S, Konrad I, Schurzinger K, et al. Platelets secrete stromal cell-derived factor 1alpha and recruit bone marrow-derived progenitor cells to arterial thrombi in vivo. J Exp Med. 2006; 203(5):1221-1233. (Pubitemid 43736592)
26. Koenen RR, von Hundelshausen P, Nesmelova IV, et al. Disrupting functional interactions between platelet chemokines inhibits atherosclerosis in hyperlipidemic mice. Nat Med. 2009;15(1):97-103.
27. Beites CL, Campbell KA, Trimble WS. The septin Sept5/CDCrel-1 competes with alpha-SNAP for binding to the SNARE complex. Biochem J. 2005; 385(2):347-353. (Pubitemid 40165066)
28. Son JH, Kawamata H, Yoo MS, et al. Neurotoxicity and behavioral deficits associated with Septin-5 accumulation in dopaminergic neurons. J Neurochem. 2005;94(4):1040-1053. (Pubitemid 41170591)
29. Beites CL, Xie H, Bowser R, Trimble WS. The septin CDCrel-1 binds syntaxin and inhibits exocytosis. Nat Neurosci. 1999;2(5):434-439. (Pubitemid 30491253)
30. Italiano JE, Jr., Richardson JL, Patel-Hett S, et al. Angiogenesis is regulated by a novel mechanism: pro- and antiangiogenic proteins are organized into separate platelet alpha granules and differentially released. Blood. 2008;111(3):1227-1233. (Pubitemid 351213404)
31. Battinelli EM, Markens BA, Italiano JE. Release of angiogenesis regulatory proteins from platelet alpha granules: modulation of physiological and pathological angiogenesis. Blood. 2011;118(5): 1359-1369.
32. Oran PE, Sherma ND, Borges CR, Jarvis JW, Nelson RW. Intrapersonal and populational heterogeneity of the chemokine RANTES. Clin Chem. 2010;56(9):1432-1441.
33. Oravecz T, Pall M, Roderiquez G, et al. Regulation of the receptor specificity and function of the chemokine RANTES (regulated on activation, normal T cell expressed and secreted) by dipeptidyl peptidase IV (CD26)-mediated cleavage. J Exp Med. 1997;186(11):1865-1872. (Pubitemid 27524596)
34. Lim JK, Lu W, Hartley O, DeVico AL. N-terminal proteolytic processing by cathepsin G converts RANTES/CCL5 and related analogs into a truncated 4-68 variant. J Leukoc Biol. 2006;80(6): 1395-1404. (Pubitemid 44904978)
35. Hannigan GE, Leung-Hagesteijn C, Fitz-Gibbon L, et al. Regulation of cell adhesion and anchorage-dependent growth by a new beta1-integrin-linked protein kinase. Nature. 1996;379:91-96. (Pubitemid 26008142)
36. Wickström SA, Lange A, Montanez E, Fassler R. The ILK/PINCH/Parvin complex: the kinase is dead, long live the pseudokinase! EMBO J. 2010; 29(2):281-291.
37. Fukuda K, Knight JDR, Piszczek G, Kothary R, Qin J. Biochemical, proteomic, structural, and thermodynamic characterizations of integrin-linked kinase (ILK). J Biol Chem. 2011;286(24): 21886-21895.
38. Hannigan GE, McDonald PC, Walsh MP, Dedhar S. Integrin-linked kinase: Not so 'pseudo'after all. Oncogene. 2011;30:4375-4385.
39. Tucker KL, Sage T, Stevens JM, et al. A dual role for integrin-linked kinase in platelets: regulating integrin function and alpha-granule secretion. Blood. 2008;112(12):4523-4531.
40. Meder B, Huttner IG, Sedaghat-Hamedani F, et al. PINCH proteins regulate cardiac contractility by modulating integrin linked kinase-protein kinase B signaling. Mol Cell Biol. 2011;31:3424-3435.
41. Parguiña AF, Grigorian-Shamajian L, Agra RM, et al. Proteins involved in platelet signaling are differentially regulated in acute coronary syndrome: a proteomic study. PLoS One. 2010; 5(10):e13404.
42. Parguiña AF, Grigorian-Shamagian L, Agra RM, et al. Variations in platelet proteins associated with ST-elevation myocardial infarction: novel clues on pathways underlying platelet activation in acute coronary syndromes. Arterioscler Thromb Vasc Biol. 2011;31(12):2957-2964.
43. Shimazawa M, Suemori S, Inokuchi Y, et al. A novel calpain inhibitor, ((1S)-1-((((1S)-1-Benzyl-3-cyclopropylamino-2,3-di-oxopropyl) mino)carbony l)-3-methylbutyl)carbamic acid 5-methoxy-3-oxapentyl ester (SNJ-1945), reduces murine retinal cell death in vitro and in vivo. J Pharmacol Exp Ther. 2010;332(2):380-387.
44. Nangle MR, Cotter MA, Cameron NE. The calpain inhibitor, A-705253, corrects penile nitrergic nerve dysfunction in diabetic mice. Eur J Pharmacol. 2006;538(1-3):148-153.
45. Subramanian V, Uchida HA, Ijaz T, et al. Calpain inhibition attenuates angiotensin II-induced abdominal aortic aneurysms and atherosclerosis in LDL receptor deficient mice. J Cardiovasc Pharmacol. 2012;59(1):66-76.
46. Scalia R, Gong Y, Berzins B, et al. A novel role for calpain in the endothelial dysfunction induced by activation of angiotensin II type 1 receptor signaling / novelty and significance. Circ Res. 2011; 108(9):1102-1111.
47. Donkor IO. Calpain inhibitors: a survey of compounds reported in the patent and scientific literature. Expert Opin Ther Pat. 2011;21(5):601-636.